The association of cancer with hormones is well known and long-documented. For example, sex hormones are known to affect breast as well as prostate cancers. This association has generated several effective therapeutic agents e.g. the estrogen-lowering drug Femara used in breast cancer and many others.
A recent discovery of yet another such association has opened the door for a new therapeutic approach. This broader association sheds lights the impact of thyroxine on a long list of aggressive cancers including GBM, lung and many others as well as metastases. Interestingly, this discovery has offered an explanation to numerous previously unexplained medical observations.
Musli's technology harnesses this discovery to offer a novel therapeutic approach of thyroxine deprivation. Musli's fixed-dose combination therapy effectively induces hypothyroxinemia with promising preliminary oncological results.